Cancer
Who we are
DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The Drug Rediscovery Protocol (DRUP Trial)
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Adoptive Cell Therapy Across Cancer Diagnoses
